Stock JAZZ JAZZ PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Real-time Estimate Cboe BZX
Other stock markets
 02:10:55 2024-05-06 pm EDT 		5-day change 1st Jan Change
110.6 USD +0.56% Intraday chart for Jazz Pharmaceuticals plc -0.68% -10.20%
May. 03 UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating MT
May. 02 Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jazz Pharmaceuticals : Corporate Overview
PU
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating
MT
Jazz Pharmaceuticals : Announces First Quarter 2024 Financial Results
PU
Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook
MT
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35
MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q1 Revenue $902M, vs. Street Est of $954.3M
MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q1 EPS $2.68, vs. Street Est of $4.18
MT
Transcript : Jazz Pharmaceuticals plc, Q1 2024 Earnings Call, May 01, 2024
Jazz: Q1 Earnings Snapshot
AQ
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
PR
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
PR
Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024
CI
Jazz Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Jazz Pharmaceuticals to Present Data across Growing Oncology Pipeline and Portfolio at ASCO 2024
AQ
The PharmaMar Group presents financial results for the first quarter of 2024
AQ
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
PR
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment
MT
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
CI
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating
MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. News Jazz Pharmaceuticals plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW